Logo Image
Opinion|Videos|August 30, 2024

Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.

Episodes in this series

Video content above is prompted by the following question:

  • What are some challenges or limitations you have encountered when using the Gleason score when assessing risk in your prostate cancer patients?
  • In your clinical experience, have biomarkers guided your treatment recommendations? If so which one(s)?

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more